You are here

Article Text

Article menu
Download PDFPDF
Original article
Cadherin 5 expression correlates with poor survival in human gastric cancer
  1. Kyoko Higuchi1,
  2. Mikito Inokuchi1,
  3. Yoko Takagi2,
  4. Toshiaki Ishikawa2,
  5. Sho Otsuki1,
  6. Hiroyuki Uetake2,
  7. Kazuyuki Kojima3,
  8. Tatsuyuki Kawano1
  1. 1Department of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo, Japan
  2. 2Department of Surgical Specialties, Tokyo Medical and Dental University, Tokyo, Japan
  3. 3Department of Minimally Invasive Surgery, Tokyo Medical and Dental University, Tokyo, Japan
  1. Correspondence to Dr Mikito Inokuchi, Department of Gastric Surgery, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8519, Japan; m-inokuchi.srg2{at}tmd.ac.jp

Abstract

Aims Although expressed in tumour cells of various malignancies, cadherin 5 (CDH5), also known as vascular endothelial cadherin, plays an important role in homotypic cell–cell adhesion among epithelial cells. However, the clinical significance of CDH5 expression in gastric cancer has not been sufficiently demonstrated. In this study, CDH5 expression in gastric cancer was evaluated and the correlations between CDH5 expression and the clinicopathological features and outcomes of the disease were examined.

Methods Differentiated-type gastric adenocarcinomas obtained from 102 patients who underwent gastrectomy were analysed. CDH5 expression was assessed by immunohistochemical staining of the membranes of the cancer cells.

Results High CDH5 expression was significantly associated with the following clinicopathological variables related to tumour progression: depth of invasion (p=0.012), venous invasion (p=0.013), lymphatic invasion (p=0.001), metastatic lymph nodes (p=0.009), pathological stage (p=0.008) and distant metastasis or recurrent disease (p=0.009). Patients with high CDH5 expression had significantly poorer disease-specific survival (p=0.021), although CDH5 was not determined to be an independent prognostic factor by multivariate analysis.

Conclusions CDH5 may play a key role in the progression or metastasis of differentiated-type gastric cancer and serve as a target for its treatment.

  • GASTRIC CANCER
  • GASTRIC PATHOLOGY
  • IMMUNOHISTOCHEMISTRY

https://doi.org/10.1136/jclinpath-2016-203640

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Handling editor Cheok Soon Lee

    • Contributors KH and MI were responsible for drafting the manuscript. KH and YT contributed to the immunohistochemistry analysis. KH, MI, TI and HU contributed to the analysis and interpretation of data. SO, KK, HU and TK contributed in conducting the study. All the authors have read and approved the final manuscript.

    • Competing interests None declared.

    • Ethics approval This study was approved by the Institutional Review Board of Tokyo Medical and Dental University.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.